Glucagon-like Peptide 1 (GLP-1) Analogues Market Size, Share & Forecast 2024-2031
The Glucagon-like Peptide 1 (GLP-1) Analogues Market study by DataM Intelligence provides a comprehensive analysis of the market, delivering valuable insights, detailed statistics, historical trends, and industry-backed market data. The report explores the competitive landscape, focusing on key players in the industry. It evaluates aspects such as product offerings, pricing models, financial performance, product portfolios, growth strategies, and regional expansion to offer a thorough understanding of market dynamics and future trends.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID) @ https://datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?sz
What is the projected growth of the Global Glucagon-like Peptide 1 (GLP-1) Analogues market?
The Global Glucagon-like Peptide 1 (GLP-1) Analogues Market reached US$51.2 billion in 2023 and is expected to reach US$190.48 billion by 2031, growing at a CAGR of 17.9 % during the forecast period 2024-2031.
What is Glucagon-like Peptide 1 (GLP-1) Analogues Market?
The Glucagon-like Peptide 1 (GLP-1) Analogues market focuses on medications that regulate blood sugar levels and support weight management, primarily for diabetes and obesity treatment. Driven by rising diabetes prevalence, obesity concerns, and advancements in drug formulations, the market is expanding. However, high treatment costs, regulatory hurdles, and potential side effects pose challenges.
Who are the major players in the Glucagon-like Peptide 1 (GLP-1) Analogues market?
The prominent players in Glucagon-like Peptide 1 (GLP-1) Analogues market research report are:
Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm.Co., Ltd., Amgen Inc., Gmax Biopharm., and Sciwind Biosciences Co., Ltd. among others.
The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world.
Key Development
In August 2024, Metsera, a newly launched clinical-stage biopharmaceutical company, secured $290 million in funding to advance innovative treatments for obesity and metabolic diseases, with a strong focus on GLP-1 receptor agonists.
In June 2024, Teva Pharmaceuticals introduced the first generic version of a GLP-1 receptor agonist in the U.S., specifically liraglutide 1.8 mg. This milestone in diabetes treatment offers a more affordable option for patients managing type 2 diabetes.
Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/glucagon-like-peptide-1-analogues-market
Market Segments
By Product: Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Others.
By Type: Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist.
By Route of Administration: Subcutaneous, Oral.
By Application: Type 2 Diabetes Mellitus, Obesity, Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
The Glucagon-like Peptide 1 (GLP-1) Analogues industry is experiencing rapid growth, driven by advancements in medical technologies, increased demand for innovative therapies, and a rising focus on patient-centered care. As these sectors evolve, the need for comprehensive market analysis becomes crucial to understand trends, regulatory changes, and emerging opportunities.
Regions Covered:
The global Glucagon-like Peptide 1 (GLP-1) Analogues Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.
☞ North America - US, Canada, Mexico
☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe
☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific
☞ South America- Brazil, Argentina, Colombia, Rest of South America
☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel
Speak to Our Senior Analyst and Get Customization in the report as per your requirements @ https://datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market
Benefits of the Report:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.
➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian